Sequential high dose-density chemotherapy with two active regimens for advanced small cell lung cancer.

16 patients with advanced small cell lung cancer were 2 treated with a comb ination of cyclophosphamide (1000 mg/m(2) day 1) epidoxorubicin (60 mg/m(2) day 1) and vincristine (1.4 mg/m(2) day 1) every 14 days for; sir cycles f ollowed by a combination of cisplatin (40 mg/m(2) days 1 & 2) and etoposide (100 mg/m(2) days 1-3) every 14 days for four cycles. Shortening of interv als was obtained with the prophylactic employment of granulocyte colony-sti mulating factor (filgrastim, 300 mcg subcutaneously from day 5 to dsy 10). In 11 patients ratio between actually delivered dose intensity and planned dose intensity of >80% was obtained. Toxicity was acceptable and no life-th reatening toxicities were observed. An objective response (partial or compl ete) was observed in 11 patients. The new regimen, incorporating the concep ts of dose-intensification and sequential administration of regimens, is fe asible and may be considered for further studies.